Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects

This report describes phase 1 clinical trials performed to assess interactions of oral isavuconazole at the clinically targeted dose (200 mg, administered as isavuconazonium sulfate 372 mg, 3 times a day for 2 days; 200 mg once daily [QD] thereafter) with single oral doses of the cytochrome P450 (CY...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Pharmacol Drug Dev
Egile Nagusiak: Yamazaki, Takao, Desai, Amit, Goldwater, Ronald, Han, David, Howieson, Corrie, Akhtar, Shahzad, Kowalski, Donna, Lademacher, Christopher, Pearlman, Helene, Rammelsberg, Diane, Townsend, Robert
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2016
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5297975/
https://ncbi.nlm.nih.gov/pubmed/27273149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.281
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak